Glucocorticoid-induced bone fragility: New insights

Research output: Chapter in Book/Report/Conference proceedingConference contribution

35 Scopus citations


Glucocorticoid (GC) use results in rapid bone loss and an elevated risk of fracture. The excess bone fragility from GC treatment is multifactorial. GCs increase bone remodeling through reductions in gonadal hormones, elevations in PTH from negative calcium balance, early stimulation of osteoclast maturation and activity, and delayed, sustained reduction in osteogenesis and osteoblast activity. GCs also alter the metabolism of osteocytes so that increased osteocyte lacunae size, with demineralization around the osteocyte and reduced elastic modulus, is observed in a mouse model of GC-induced bone loss. In summary, GC effects on bone fragility are multifactorial, and additional studies are now under way to clarify how GCs alter osteocyte metabolism and result in reduction in localized bone strength.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Number of pages3
StatePublished - Mar 2010

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)00778923
ISSN (Electronic)17496632


  • Bone fragility
  • Glucocorticoids
  • Osteoporosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Glucocorticoid-induced bone fragility: New insights'. Together they form a unique fingerprint.

Cite this